Post-ERCP Pancreatitis Incidence
The incidence of pancreatitis after ERCP is approximately 3.5% in general populations, though rates vary from 1.6% to 16% depending on patient selection and risk factors 1, 2.
General Population Data
Based on the highest quality guideline evidence, pancreatitis occurs in 3.47% (95% CI: 3.19%-3.75%) of ERCP procedures in a systematic survey of 21 prospective studies involving 16,855 patients 1. A large retrospective single-center study with 11,497 procedures over 12 years reported a similar rate of 3.6% 1.
The ACR Appropriateness Criteria guidelines cite an incidence of approximately 3.5%, with a range of 1.6%-15.7% depending on patient selection 2. Another guideline source reports major complication rates (including pancreatitis, cholangitis, hemorrhage, and perforation) between 4-5.2% for all ERCP complications combined 3.
Special Population: Primary Sclerosing Cholangitis (PSC)
In PSC patients specifically, the risk for post-ERCP pancreatitis ranges from 1% to 7%, though diagnostic criteria vary between studies 1. The overall risk of adverse events in PSC patients has varied from 1.8% to 18.4% in smaller studies, which is notably higher than for other indications 1.
Key Risk Factors That Increase Incidence
The following factors substantially increase pancreatitis risk and explain the wide variation in reported rates:
Patient-Related Factors:
- Female sex (OR: 2.6) 1
- Age ≤60 years (OR: 1.81) 4
- Prior acute pancreatitis (OR: 2.59) 4
- Suspected sphincter of Oddi dysfunction (OR: 1.78-3.11) 5, 4
- Native papilla (increases risk; prior sphincterotomy decreases it) 1
Procedure-Related Factors:
- Guidewire passage into pancreatic duct (OR: 8.2 for guidewire in PD; OR: 2.18 for any PD passage) 1, 4
- Difficult cannulation (OR: 2.60-5.72) 6, 4
- Precut biliary/pancreatic sphincterotomy (OR: 1.98-2.49) 1, 5
- Endoscopic papillary balloon dilation (OR: 2.85-9.24) 6, 5, 4
- Pancreatic duct injection/contrast injection (OR: 2.56-3.22) 6, 5
- First ERCP with native papilla (OR: 1.91) 4
Clinical Context
Post-ERCP pancreatitis is the most common and feared complication of ERCP 1. The wide range in reported incidence (1.6%-16%) reflects differences in:
- Patient risk profiles
- Procedural complexity
- Endoscopist experience
- Diagnostic criteria used
- Whether prophylactic measures were employed
Recent evidence suggests the incidence has declined over time with improved patient selection, equipment, and techniques—from 4.09% in early stages to 1.80% in more recent periods 5.
Prevention Implications
All patients undergoing ERCP should receive rectal NSAIDs (100 mg diclofenac or indomethacin) immediately before or after the procedure unless contraindicated 1. For high-risk patients (those with the factors listed above), prophylactic 5-Fr pancreatic stent placement should be strongly considered 1.